s6y

10-K Annual Report for period ending Mar 31, 2019

Filed
Period
Accession number
0001213900-19-011224

Documents

  1. ANNUAL REPORT 10-K
  2. LICENSE, SUPPLY AND DISTRIBUTION AGREEMENT EFFECTIVE APRIL 9, 2019 BY AND BETWEEN ELITE PHARMACEUTICALS, INC., AND ELITE LABORATORIES, INC. AND LANNETT COMPANY, INC., USA EX-10.49
  3. LICENSE, SUPPLY AND DISTRIBUTION AGREEMENT EFFECTIVE MARCH 6, 2019 BY AND BETWEEN ELITE PHARMACEUTICALS, INC., AND ELITE LABORATORIES, INC. AND LANNETT COMPANY, INC., USA EX-10.50
  4. DEVELOPMENT AGREEMENT EFFECTIVE DECEMBER 3, 2018 BY AND BETWEEN MIKAH PHARMA LLC AND ELITE LABORATORIES, INC. (PORTIONS OF THIS AGREEMENT HAVE BEEN REDACTED IN COMPLIANCE WITH REGULATION S-K ITEM 601(B)(10))* EX-10.51
  5. SUBSIDIARY OF THE COMPANY EX-21
  6. CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM EX-23.1
  7. CERTIFICATION EX-31.1
  8. CERTIFICATION EX-31.2
  9. CERTIFICATION EX-32.1
  10. CERTIFICATION EX-32.2
  11. XBRL INSTANCE FILE EX-101.INS
  12. XBRL SCHEMA FILE EX-101.SCH
  13. XBRL CALCULATION FILE EX-101.CAL
  14. XBRL DEFINITION FILE EX-101.DEF
  15. XBRL LABEL FILE EX-101.LAB
  16. XBRL PRESENTATION FILE EX-101.PRE

On sec.gov